| Literature DB >> 36160715 |
Xiaoyu Xu1, Cheng Zhang1, Ning Wang1, Yu Xu2,3, Guoyi Tang1, Lin Xu1, Yibin Feng1.
Abstract
Dendrobium officinale has a long history of being consumed as a functional food and medicinal herb for preventing and managing diseases. The phytochemical studies revealed that Dendrobium officinale contained abundant bioactive compounds, such as bibenzyls, polysaccharides, flavonoids, and alkaloids. The experimental studies showed that Dendrobium officinale and its bioactive compounds exerted multiple biological properties like antioxidant, anti-inflammatory, and immune-regulatory activities and showed various health benefits like anticancer, antidiabetes, cardiovascular protective, gastrointestinal modulatory, hepatoprotective, lung protective, and neuroprotective effects. In this review, we summarize the phytochemical studies, bioactivities, and the mechanism of actions of Dendrobium officinale, and the safety and current challenges are also discussed, which might provide new perspectives for its development of drug and functional food as well as clinical applications.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36160715 PMCID: PMC9507758 DOI: 10.1155/2022/6293355
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1The chemical structures of several compounds found in different parts of Dendrobium officinale.
Figure 2The gastrointestinal modulatory activities of Dendrobium officinale via several pathways.
Figure 3A summary of the health benefits of Dendrobium officinale.
The health benefits and related molecular mechanisms of Dendrobium officinale extracts.
| Type of study | Object | Dosage | Effects | Potential mechanisms | References |
|
| |||||
| In vivo | Male STZ-induced diabetic C57BL/6 mice | 300 and 700 mg/kg b.w. | Decreased the levels of blood glucose | ↑ Citrate, pyruvate, alanine, isoleucine, histidine, and glutamine in serum | [ |
| In vivo | Male STZ-induced type 1 diabetic Sprague-Dawley rats | 1 g/kg b.w. | Decreased the levels of serum TC, TG, BUN, and CREA | ↑ GSH-Px | [ |
|
| |||||
| In vivo | Male and female Kunming mice | 2.37 g/kg b.w. | Increased the diversity of intestinal mucosal flora | ↑ | [ |
| In vivo | Male ICR mice | 0.2 and 0.6 g/kg b.w. | Regulated the gut microbiota | NA | [ |
|
| |||||
| In vivo | Male Kunming mice | 75, 150, and 300 mg/kg b.w. | Protected against myocardial ischemia | ↑ SOD | [ |
| In vivo | Male STZ-induced diabetic Kunming mice | 75, 150, and 300 mg/kg b.w. | Decreased the ratio of heart to body weight | ↑ T-SOD | [ |
| In vivo | Male STZ-induced diabetic Kunming male mice | 75, 150, and 300 mg/kg b.w. | Decreased the ratio of heart to body weight | ↑ T-SOD | [ |
| In vivo | Male Sprague-Dawley rats with ACHSFD-induced metabolic hypertension | 400 and 600 mg/kg b.w. | Lowered blood pressure | ↑ SCFA-GPCR43/41 pathway | [ |
| In vivo | HFD/STZ-induced diabetic mice | 75, 150, and 300 mg/kg b.w. | Reduced cardiac injury and fibrosis | ↑ PPAR- | [ |
|
| |||||
| In vivo | Male Kunming mice | 50, 100, and 200 mg/kg b.w. | Mitigated the alcohol-induced liver injury | ↑ GSH, SOD, GSH-Px, and CAT | [ |
|
| |||||
| In vivo | Male and female neonatal Sprague-Dawley rats | 75, 150, and 300 mg/kg b.w. | Protected against hypoxic-ischemic brain damage | ↑ SOD | [ |
| In vivo | Male ICR mice | 1 and 3 g/kg b.w. | Reduced the depression-like behavior (decreased sucrose consumption and increased immobile time) | ↑ NGF and BDNF | [ |
| In vitro | PC12 cells | 1, 3, and 10 | Potentiated the neurite outgrowth treatment | ↑ Neurofilaments | |
|
| |||||
| In vivo | Male BALB/c mice | Improved the fatigue resistance | ↑ PGC-1 | [ | |
NA: not applicable.
The health benefits and related molecular mechanisms of Dendrobium officinale polysaccharides.
| Type of study | Object | Dosage | Effects | Potential mechanisms | References |
|
| |||||
| In vitro | Colon cancer cell line CT26 cells | 0, 400, and 800 | Induced mitochondrial dysfunction and autophagy | ↑ ROS-AMPK-autophagy pathway | [ |
| In vitro | Colon cancer cell line HT-29 cells | 25, 50, 100, 200, and 400 | Inhibited the proliferation of cells | ↑ Mitochondria-dependent intrinsic apoptotic pathway | [ |
| In vivo | Zebrafish | 27.8, 83.3, and 250 | Inhibited tumor metastasis | NA | |
| In vivo | Male BALB/c mice with AOM/DSS-induced colorectal cancer | 50, 100, and 200 mg/kg b.w. | Alleviated chronic colitis and colon damage | ↑ ZO-1 and occludin | [ |
| In vivo | Male Wistar rats | 2.4 and 4.8 g/kg b.w | Inhibited the gastric carcinogenesis | ↑ GSH-Px and IL-2 | [ |
| In vitro | Liver hepatocellular carcinoma cell line HepG2 cells | 50, 100, 200, and 400 | Inhibited cell growth | ↑ ROS | [ |
| In vitro | Human osteosarcoma cell line U2OS and Saos-2 cells | 12.5, 25, 50, 100, and 200 | Inhibited the proliferation of cells | ↑ p53, Bax, and Bak | [ |
| In vitro | Human cervical carcinoma HeLa cells | 25, 50, 100, 200, and 400 | Inhibited the proliferation of cells | ↑ ERK, JNK, and p38 | [ |
| In vivo | Male Wistar rats | 2.4, 4.8, and 9.6 g/kg b.w. | Prevented MNNG-induced PLGC | ↑ Nrf2 signaling pathway | [ |
| In vivo | Male Sprague-Dawley rats | 2.4, 4.8, and 9.6 g/kg b.w. | Inhibited MNNG-induced PLGC | ↓ Wnt2 | [ |
|
| |||||
| In vivo | Streptozotocin-induced diabetic male Sprague-Dawley rats | 25 and 100 mg/kg b.w. | Lowered the fasting blood sugar levels | Ca2+/CaM/CaMKII and MAPK signaling pathways | [ |
| In vitro | Murine enteroendocrine cell line STC-1 cells | 0, 0.2, 2, 20, 200, and 2000 | |||
| In vivo | Streptozotocin-induced diabetic male Wistar rats | 20, 40, 80, and 160 mg/kg b.w | Decreased the levels of fasting blood glucose, insulin, glycated serum protein, and serum lipid profile | ↑ SOD | [ |
| In vivo | Male HFD/STZ-induced diabetic C57BL/6J mice | 100, 200, and 400 mg/kg b.w. | Promoted hepatic glycogen synthesis | NA | [ |
|
| |||||
| In vitro | Human gastric mucosal epithelial HFE145 cells | 31.25, 62.5, 125, 250, and 500 | Ameliorated H2O2-induced apoptosis | ↑ Bcl-2 | [ |
| In vivo | Male Sprague-Dawley rats | 124 and 248 mg/kg b.w. | Reduced the ethanol-induced gastric mucosal injury, mucin loss, and apoptosis | ↓ The ratio of Bax to Bcl2 | |
| In vivo | Female ICR mice | 0.5 and 2 mg/kg b.w. | Regulated the small intestinal immune function | NA | [ |
| In vivo | Male BALB/c mice | 200 mg/kg b.w. | Improved the diversity of gut microbiota | ↑ SCFAs | [ |
| In vivo | Male Sprague-Dawley rats | 100 and 400 mg/kg b.w. | Reduced gastric mucosal injury score and pathological injury | ↑ p-AMPK, LC3 | [ |
| In vitro | Human gastric epithelial cell line GES-1 cells | 62.5, 125, and 250 | Alleviated cell apoptosis | ||
|
| |||||
| In vitro | H9c2 cardiomyocytes | 6.25, 12.5, and 25 | Increased the survival rate of cells and antioxidant enzyme activity | ↑ The ratios of p-Akt to Akt and p-ERK to ERK | [ |
|
| |||||
| In vivo | Male Wistar rats | 20, 40, 80, and 160 mg/kg b.w. | Ameliorated the liver metabolism | NA | [ |
| In vivo | Male ICR mice | 50, 100, and 200 mg/kg b.w. | Attenuated acetaminophen-induced liver injury | ↑ GSH and CAT | [ |
| In vivo | Male C57BL/6J | 100, 200, and 400 mg/kg b.w. | Maintained the balance of GSH content in liver | NA | [ |
| In vivo | Male ICR mice | 0.6 g/kg b.w. | Decreased TG and FA content in the liver | ↑ CPT1- | [ |
|
| |||||
| In vivo | Male Sprague-Dawley rats | 200 mg/kg b.w. | Alleviated bleomycin-induced pulmonary inflammation and fibrosis | ↓ TGF- | [ |
| In vitro | Human bronchial epithelial cells | 0.01, 0.1, and 1 | Ameliorated the cigarette smoke-induced mucus hypersecretion and viscosity | ↓ MUC5AC | [ |
| In vivo | Male Sprague-Dawley rats | 50 and 200 mg/kg b.w. | |||
| In vitro | Mouse lung epithelial cells | 0.01, 0.1, and 1 | Ameliorated the lung functions and inflammation in chronic obstructive pulmonary disease | ↑ AQP5 | [ |
| In vivo | Sprague-Dawley rats | 5, 10, and 20 mg/mL | |||
| A randomized, double-blind, and placebo-controlled clinical trial | Active cigarette smokers over 40 years old with mild airflow obstruction | 1.2 g thrice daily | |||
|
| |||||
| In vivo | Pentetrazol-induced epileptic male Sprague-Dawley rats | 1.5 g/kg b.w. | Reduced brain inflammation and seizures | ↓ IL-1 and TNF- | [ |
| In vivo | Female Kunming mice | 140 mg/kg b.w. | Ameliorated the learning and memory disability | ↑ Nrf2/HO-1 pathway | [ |
|
| |||||
| In vitro | Bone marrow mesenchymal stem cells | 100, 200, and 400 | Enhanced osteogenic differentiation of BMSCs | ↑ Nrf2 signaling pathway | [ |
| In vivo | Fifteen-month-old mice | 150 mg/kg b.w. | Increased the bone mass | ||
| In vitro | RAW264.7 cells | 40 and 80 | Alleviated estradiol deficiency | NA | [ |
| In vivo | Female Wistar rats | 150, 300, and 600 mg/kg b.w. | |||
|
| |||||
| In vitro | Hepatocytes, C2C12 myoblasts, and 3T3-L1 preadipocytes | 200 | Ameliorated the insulin resistance | ↑ PPAR- | [ |
| In vivo | Male C57BL/6 mice and ob/ob mice | 150 mg/kg b.w. | Reduced insulin resistance and visceral adipose tissue inflammation | ||
|
| |||||
| In vivo | Male and female ICR mice | 29, 57, and 114 mg/kg b.w. | Attenuated constipation | ↑ Motilin, gastrin, acetyl cholinesterase, and substance P | [ |
NA: not applicable.